DCTH · Delcath Systems

The thesis

Delcath Systems is more likely than not to beat the S&P 500 over the next three months. Demand for its HEPZATO KIT liver treatment pushed third-quarter revenue to $35.1 million and 2026 guidance to $115–117 million on 9 November 2026. The full-year report, expected around March 2027, settles whether the holiday-season fourth quarter holds that range.

The rating is Medium because the business evidence is strong but the next three months hold a seasonally weaker quarter and no scheduled earnings report. Revenue was $35.102 million in the third quarter, against $20.563 million a year earlier, and diluted earnings were $0.17 per share, according to Delcath's 8-K of 9 November 2026. Analysts had expected a loss of $0.09 per share on $26.0 million of revenue, per Benzinga.

The price already reflects much of that beat. The shares closed at $14.93 on 6 November 2026, before the report, and at $21.38 on 12 November 2026, after touching a 52-week intraday high of $22.51 that day. Two of the post-report analyst targets, BTIG's $25 and Canaccord Genuity's $27, now sit within reach of that close.

Bullish and bearish views on Delcath Systems, Inc.

The bull case on Delcath Systems, Inc. (DCTH), in brief: procedure revenue grew 69% year over year. The bear case: guidance implies a weaker fourth quarter.

Bull case

• Procedure revenue grew 69% year over year. Delcath's 9 November 2026 release reported third-quarter HEPZATO KIT revenue of $32.7 million, against $19.3 million a year earlier. CHEMOSAT, the European version, contributed $2.4 million.
• Guidance rose again in November. Delcath guided to $104–108 million on 6 August 2026 and raised that to $115–117 million on 9 November 2026. The new range assumes at least 41% HEPZATO KIT volume growth and 87–89% gross margin; analysts had expected $106.5 million, per Benzinga.
• The business now earns cash. Third-quarter net income was $7.0 million, adjusted EBITDA (earnings before interest, tax, depreciation and amortization) $11.5 million and operating cash flow $8.2 million, per the 9 November 2026 release.
• The balance sheet funds the pipeline. Cash and investments were $104.3 million at 30 September 2026, up from $95.9 million at 30 June 2026, and Delcath has no debt.
• Every post-report analyst action was positive. H.C. Wainwright kept a Buy rating and raised its target to $36 from $32 on 10 November 2026, per MarketBeat. Canaccord Genuity kept a Buy rating and raised its target to $27 on 11 November 2026, per company news. BTIG raised its target to $25 from $21 on 9 November 2026 and reiterated it on 12 November 2026. MarketBeat put the consensus target at $29.33 across four ratings on 11 November 2026.
• The center network is still growing. Delcath had 33 active U.S. treatment centers at the 9 November 2026 report and targets at least 36 by year-end. Management said two new sites already have patients scheduled.
• Pipeline readouts are moving closer. On the 9 November 2026 call, management expected the colorectal trial's interim analysis around mid-2027 and a cholangiocarcinoma (bile duct cancer) trial filing in early 2027.

Bear case

• Guidance implies a weaker fourth quarter. The raised range implies fourth-quarter revenue of $25.8–27.8 million, against $35.1 million in the third quarter. Management blamed about two weeks of lost holiday scheduling on the 9 November 2026 call.
• Patient starts usually fall late in the year. Management said fourth-quarter 2025 new patient starts ran at about 0.3–0.35 per site per month, against about 0.6 in the third quarter of 2026. Asked about October, it gave no figures and said it was "very comfortable" with guidance.
• Spending keeps rising. Third-quarter research and development expense was $11.0 million, against $8.0 million a year earlier. Management said on 9 November 2026 that research spending will rise quarter over quarter into 2027.
• Near-term estimates moved down. H.C. Wainwright cut its second-quarter 2027 earnings estimate to $0.11 per share from $0.12 in a 10 November 2026 note, per MarketBeat, while raising later-year figures.
• The breast cancer trial is slow. Management said on 9 November 2026 that enrollment was slower than expected and gave no interim timing.
• Revenue rests on one product. HEPZATO KIT supplied $32.7 million of the $35.1 million third-quarter total, so any problem with access, safety or payment would hit most of the revenue.

Price setup

The shares closed at $14.93 on 6 November 2026 and at $20.27 on 9 November 2026, the session of the report. They closed at $20.10 on 10 November 2026, $21.77 on 11 November 2026 and $21.38 on 12 November 2026. The 12 November 2026 close sits 5.0% below that day's intraday 52-week high of $22.51. The 52-week closing low was $8.19 on 20 November 2025.

Over three months the shares rose 27.8%, from a close of $16.73 on 14 August 2026; most of that came in the sessions after the report. The last close is well above the 50-day moving average of $15.80 and the 200-day moving average of $12.66, both as of 12 November 2026 from adjusted daily closes.

The $14.93 pre-report close marks a full reversal of the post-report gain. No earnings report is scheduled until around March 2027, so company news before then comes mainly from the 17 November 2026 Craig-Hallum conference and the year-end center count.

Catalysts ahead

• 17 November 2026: Craig-Hallum Alpha Select Conference, New York. The last scheduled investor appearance announced for November 2026; management may update center activations toward the year-end target of at least 36.
• ~31 December 2026 (est.): Year-end deadline for Delcath's target of at least 36 active U.S. treatment centers. Shows whether the network keeps expanding from 33 centers at the third-quarter report, which supports 2027 volume.
• ~1 March 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether 2026 revenue lands within the $115–117 million guidance and how far the holiday quarter fell from the third quarter.

What would change the view

A daily close below $17.00, which would erase most of the gain from the $14.93 close on 6 November 2026. Separately, 2026 revenue below the $115 million guidance floor set on 9 November 2026 would break the operating case.

The risks this note tracks, each with what would confirm it:

• Fourth-quarter patient starts fall further than guidance assumes, and 2026 revenue misses the raised range. Confirmed by: a preliminary or reported fourth-quarter revenue figure below the implied $25.8 million, or 2026 revenue below $115 million.
• Center activations stall and leave little room for 2027 volume growth. Confirmed by: a year-end active center count well short of the 36 target, or little change from the 33 reported on 9 November 2026.
• Rising research and selling costs erode profit as clinical programs expand. Confirmed by: a quarter with negative operating cash flow, against $8.2 million positive in the third quarter of 2026, or a guidance change dropping positive adjusted EBITDA.
• Reliance on HEPZATO leaves revenue exposed to any access or safety problem. Confirmed by: a company or regulatory disclosure of a safety restriction or reimbursement change that reduces HEPZATO use.
• Clinical programs slip, removing the 2027 pipeline readouts from the case. Confirmed by: management moving the colorectal interim analysis beyond mid-2027 or the cholangiocarcinoma filing beyond early 2027.

What it trades with

Delcath's shares trade mainly on the company's own news. The jump from $14.93 to $20.27 came in the session of the 9 November 2026 report, a day Benzinga reported a 2.1% S&P 500 gain. With a market value of $703.37 million on 10 November 2026, per MarketBeat, the stock is exposed to swings in investor appetite for small-cap healthcare. Its revenue depends on hospital scheduling and on liver-directed treatment of metastatic uveal melanoma, an eye cancer that has spread to the liver, so it has no close listed peer among oncology drug developers.